Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
November 01, 2018 08:05 ET
|
Novan, Inc.
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
Novan Creates Dedicated Women’s Health Business Unit
October 25, 2018 07:05 ET
|
Novan, Inc.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
October 08, 2018 08:00 ET
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
GeoVax and Emory University to Collaborate on HPV Therapeutic Program for Head and Neck Cancers
July 30, 2018 09:00 ET
|
GeoVax, Inc.
GeoVax Continues Expansion of its MVA-VLP Vaccine Pipeline with Multiple Collaborations in Infectious Disease and Immuno-oncology ATLANTA, GA, July 30, 2018 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc....
Take the pledge: Health care professionals commit to talking to patients about HPV and cancer
June 04, 2018 14:29 ET
|
Prevent Cancer Foundation
Alexandria, Virginia, June 04, 2018 (GLOBE NEWSWIRE) -- The Prevent Cancer Foundation® is calling on health care professionals to take the pledge to talk to their patients about getting vaccinated...
Latest Book By Dr. Siavash Arani’s Reveals Assured Treatment of Genital Warts
April 07, 2018 08:13 ET
|
Warts Clinic
LOS ANGELES, April 07, 2018 (GLOBE NEWSWIRE) -- The latest book written by renowned medical doctor and Author, Dr. Siavash Arani, M.D reveals assured treatment of genital warts and Its...
Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
October 18, 2017 07:05 ET
|
Novan, Inc.
Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...
Novan Welcomes Key Opinion Leaders to New Advisory Council
April 04, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., April 04, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that the Company has formed an Advisory Council comprised of key opinion...
Novan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting
March 02, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the...
Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
March 01, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 01, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that preclinical data demonstrating the anti-viral effects of the Company’s...